Polypeptide With Localisation/Targeting Motif TRIZ Cases

This case combines RNA-guided DNA binding and transposition complexes for targeted plant genome integration with fewer harmful byproducts.

Antibodies targeting LGR5 amino acids 22–37 combine high affinity and rapid uptake for cancer-cell detection and therapy.

This case combines multiple HLA tumor antigens in one polypeptide to broaden immune coverage without fully individualized formulations.

This case combines ADGRE2 and CLEC12A targeting with engineered CAR domains to improve AML coverage and limit off-target activation.

Large nucleic acid cargo can compromise cell health; mobile genetic elements enable stable genomic integration without viral vectors.

Engineered fusion proteins and cell-specific domains direct CAR expression in NK, T, and B cells while limiting non-specific effects.

This case combines priming receptors, CARs, and FAS/PTPN2/TOX-targeting shRNA in an AND gate to improve specificity and T-cell persistence.

This case fuses BAI1 or TIM4 recognition domains with ELMO1 signaling to improve efferocytosis, protein folding, and inflammation outcomes.

A CAR plus TCR-like fusion molecule broadens tumor recognition and balances activation with persistence to address heterogeneous cancers.

TfR-binding acid alpha-glucosidase Fc proteins cross the BBB to address CNS Pompe disease.

Engineered CDRs direct TCRs toward H1047R/L PIK3CA peptides, improving cancer-cell selectivity while reducing toxicity.

A recombinant Fc receptor combines cleavage-resistant CD16 with CD64 binding to support adaptable antibody-guided immune therapy.

This case uses an anti-CD3 exosomal fusion protein to penetrate solid tumors, secrete BiTEs, and support immune-cell activation.

F6H and CPR pathways convert chrysin or apigenin in engineered hosts, enabling scalable flavonoid production without solvent extraction.

This case uses CAR/CXCR5-engineered cells to reach HIV reservoirs in B-cell follicles and sustain suppression without lifelong drugs.

FSH-ligand chimeric proteins direct modified T cells to FSHR-expressing tumors, addressing antigen scarcity in ovarian cancer.

This case combines tumor-antigen targeting with NKG2D and CD16 engagement to activate NK cells alongside anti-PD1 therapy.

Replacing Cys 430 helps refold non-toxic protease from insoluble fractions while preserving activity and increasing productivity.

The bispecific CAR design targets CD13 and TIM-3 on AML cells to improve killing while sparing normal hematopoietic stem cells.

Sequence-engineered nucleases improve delivery and editing efficiency while reducing off-target events in eukaryotic cells.

This case shows how Tim4 receptor signaling targets phosphatidylserine-expressing tumor cells while sustaining T-cell effector function.

This case combines CD70 CAR-T cells with secreted CD33 TEAMs to target CD70-low or negative cancer cells after antigen escape.

An ADP-ribose binding peptide delivers ADP-ribose to trigger cancer cell death despite PARP inhibitor resistance.

This case combines HIV CAR targeting with CMV-specific T cell recognition to improve expansion, persistence, and cytotoxicity under ART.

This case uses FOXO1-overexpressing engineered T cells to limit exhaustion, sustain memory-like subsets, and improve tumor control.

Low and heterogeneous CD70 expression can cause relapse; Ezh2 priming and anti-CD70 receptors improve tumor targeting.

This case combines BBB-penetrating peptides, albumin stability, target binding, and autophagy to degrade Tau and amyloid-beta.

This case links a TGFβ-binding extracellular domain to IL-2 receptor signaling to support T cell proliferation and effector function.

This case uses APC binding, translocation, antigen presentation, and ER retention to address toxicity and drug resistance.

This case uses recombinant adenovirus vectors to express PRRSV gp2, gp3, and gp4 without live PRRSV safety risks.

This case combines reovirus FAST proteins with recombinant oncolytic viruses to improve tumor-cell killing and metastatic cancer treatment.

This case applies a B1SP fusion protein to disrupt SEMA3C receptor signaling, inhibit cancer-cell proliferation, and reduce tumor growth.

This case uses optimized CDRs and Fc changes to preserve NGF inhibition and analgesia while limiting inflammatory reactions.

A 405 nm-cleaved mMaple3 linker enables exosomes to release therapeutic proteins in target cells with controlled delivery.

Phage-selected FOLR1 antibodies support targeted therapy, diagnostics, ADCs, and CAR approaches for FOLR1+ tumors.

Engineered CAR T cells target tumor Tregs while limiting systemic toxicity.

A baculovirus-produced glycosylated MAP1 subunit elicits humoral and Th1 responses against Ehrlichia ruminantium.

This case combines biotinylated polysaccharides with fusion proteins to strengthen T- and B-cell responses across serotypes.

PNGase F selectively releases N-glycans for chromatography and mass spectrometry, improving profile accuracy without cell lysis.

Specialized rabbit-derived molecules target anti-CD19 scFv FMC63 for precise detection and modulation of CD19-expressing cells.

This case combines cell-penetrating and exocyclic peptides to promote endosomal escape and deliver oligonucleotides into the cytosol.

Gene expression and intratumoral T-cell density guide chimeric receptor dosing to address cancer cell immune evasion.

CARs combine antigen-binding, signaling, and costimulatory domains to strengthen T-cell activity and counter solid-tumor suppression.

Engineered TnpB-family nucleases retain targeted cleavage and integration while reducing genome-editing system size for viral delivery.

This case uses HCV NS3 protease and approved inhibitors to modulate CAR activity, limiting overactivity without irreversible cell loss.

This case targets the Shh-SURF4 secretion interface with mutations, peptides, or small molecules to address ligand-dependent cancers.

This case uses non-toxic plant lectins to transport enzyme therapies across the blood-brain barrier into hard-to-target organs.

This case combines Cas12a nickase activity, reverse transcription, and pegRNA guidance to reduce off-target editing.

This case combines KQ-free PfCSP sequences with ferritin nanocages to strengthen and prolong immune protection against malaria.

This case combines optimized IRES elements, homology arms, and a small plasmid backbone to sustain circular mRNA protein expression in vivo.